Furiex ready to progress MuDelta for IBS to Phase III
This article was originally published in Scrip
Executive Summary
Furiex Pharmaceuticals has reported positive data from a Phase II proof-of-concept trial investigating its diarrhoea-predominant irritable bowel syndrome (IBS-D) treatment, MuDelta. Of note, the company said it had also performed some additional study analyses, based on discussions with the US FDA about appropriate endpoints in this indication, which could also be used in future Phase III trials.